Discover undervalued stocks with Eulerpool.

Subscribe for $2

Star Combo Pharma Stock S66.AX

Price

0.24
Today +/-
+0.00
Today %
+2.15 %

Star Combo Pharma stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Star Combo Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Star Combo Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Star Combo Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Star Combo Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Star Combo Pharma Stock Price History

DateStar Combo Pharma Price
10/6/20250.24 undefined
10/3/20250.23 undefined
10/2/20250.23 undefined
10/1/20250.23 undefined
9/30/20250.23 undefined
9/29/20250.36 undefined
9/26/20250.10 undefined
9/25/202526.67 undefined
9/24/20252.46 undefined
9/23/20250.48 undefined
9/22/20250.22 undefined
9/19/20250.22 undefined
9/17/20250.20 undefined
9/15/20250.02 undefined
9/12/202512.49 undefined
9/11/20252.09 undefined
9/10/20250.21 undefined
9/9/20250.22 undefined
9/8/20251.19 undefined

Star Combo Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Star Combo Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Star Combo Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Star Combo Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Star Combo Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Star Combo Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Star Combo Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Star Combo Pharma’s growth potential.

Star Combo Pharma Revenue, EBIT and net profit per share

DateStar Combo Pharma RevenueStar Combo Pharma EBITStar Combo Pharma Net Income
202528.24 M undefined5.43 M undefined5.25 M undefined
202426.28 M undefined1.18 M undefined747,300 undefined
202324.99 M undefined1.25 M undefined-4 M undefined
202223.91 M undefined502,200 undefined-696,400 undefined
202127.08 M undefined-1.87 M undefined-7.88 M undefined
202039.08 M undefined-1.71 M undefined-348,700 undefined
201921.59 M undefined-2.45 M undefined-1.73 M undefined
201810.9 M undefined-1.11 M undefined-1.64 M undefined
20179.84 M undefined2.45 M undefined1.64 M undefined
20169.4 M undefined2.65 M undefined1.82 M undefined
20156.7 M undefined332,000 undefined236,400 undefined
20145.06 M undefined580,000 undefined410,000 undefined

Star Combo Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
201420152016201720182019202020212022202320242025
56991021392723242628
-20.0050.00-11.11110.0085.71-30.77-14.814.358.337.69
20.0016.6744.4444.4440.0014.2910.2611.1121.7420.8319.2321.43
114443435556
0011-1-10-70-405
-----200.00-------
75.5175.5175.5175.5162.6682.1491.42134.79134.58135.08135.08135.08
- - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Star Combo Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Star Combo Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (k)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (k)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (k)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (k)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
20162017201820192020202120222023
               
0.166.218.944.6226.617.3210.399.49
24.13.092.712.522.532.744.07
000.150.150.61.920.430.23
2.242.413.474.945.384.55.374.2
9.232.232.3350.4241.4156.7136.5121
4.412.7515.6812.7835.3426.4319.0818.1
2.62.592.522.948.6913.4822.7422.72
00000000
000420.30000
000.663.22.892.510.70.69
0006.346.34000
0.080.130.51.111.460.90.920.71
2.692.723.6914.0119.3816.924.3624.12
7.0915.4719.3726.7954.7243.3243.4442.23
               
0537.3342.7667.7467.3267.2267.29
00000000
3.885.45-20.73-22.69-23.24-31.12-31.8-35.81
0000-0-0.01-0.010
00000001.61
3.8810.4516.5920.0744.536.1935.4133.09
0.91.41.722.372.032.122.342.44
61.370.747.389142.5233.5250.1288.7
11.9212.41.821.021.251.44
00000000
0.111.0300.010.670.170.170.16
2.074.432.764.874.663.554.014.33
1.130.5900.054.953.123.954.03
000729.9577.5421.520.6535.6
00.010.011.070.030.040.060.07
1.130.60.011.845.553.584.034.64
3.215.022.786.7210.227.138.048.97
7.0915.4719.3726.7954.7243.3243.4442.06
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Star Combo Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Star Combo Pharma's financial health and stability.

Assets

Star Combo Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Star Combo Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Star Combo Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Star Combo Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (k)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (k)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
00000000
00000000
00000000
00000000
00000000
00000000
00-100000
1,0000-1,000-2,000-1,000001,000
-100-4-2-7-7-2
-100-3-32-3-3
00000940
00000000
00-1,00001,000-2,00000
057133000
055126-200
-----8.00---
00000000
172-6200-20
0.150.67-2.65-6.42-3.8-6.93-6.76-0.85
00000000

Star Combo Pharma stock margins

The Star Combo Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Star Combo Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Star Combo Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Star Combo Pharma's sales revenue. A higher gross margin percentage indicates that the Star Combo Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Star Combo Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Star Combo Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Star Combo Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Star Combo Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Star Combo Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Star Combo Pharma Margin History

Star Combo Pharma Gross marginStar Combo Pharma Profit marginStar Combo Pharma EBIT marginStar Combo Pharma Profit margin
202523.73 %19.22 %18.59 %
202422.74 %4.5 %2.84 %
202320.55 %5.01 %-16.02 %
202222.31 %2.1 %-2.91 %
202113.06 %-6.92 %-29.09 %
202010.39 %-4.38 %-0.89 %
201918.15 %-11.34 %-8 %
201842.49 %-10.16 %-15.04 %
201741.09 %24.89 %16.61 %
201647.72 %28.18 %19.36 %
201521.19 %4.95 %3.53 %
201428.06 %11.46 %8.1 %

Star Combo Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Star Combo Pharma earnings per share therefore indicates how much revenue Star Combo Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Star Combo Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Star Combo Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Star Combo Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Star Combo Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Star Combo Pharma Revenue, EBIT and net profit per share

DateStar Combo Pharma Sales per ShareStar Combo Pharma EBIT per shareStar Combo Pharma Earnings per Share
20250.21 undefined0.04 undefined0.04 undefined
20240.19 undefined0.01 undefined0.01 undefined
20230.18 undefined0.01 undefined-0.03 undefined
20220.18 undefined0 undefined-0.01 undefined
20210.2 undefined-0.01 undefined-0.06 undefined
20200.43 undefined-0.02 undefined-0 undefined
20190.26 undefined-0.03 undefined-0.02 undefined
20180.17 undefined-0.02 undefined-0.03 undefined
20170.13 undefined0.03 undefined0.02 undefined
20160.12 undefined0.04 undefined0.02 undefined
20150.09 undefined0 undefined0 undefined
20140.07 undefined0.01 undefined0.01 undefined

Star Combo Pharma business model

Star Combo Pharma is one of the most popular companies on Eulerpool.com.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Star Combo Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Star Combo Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Star Combo Pharma shares outstanding

The number of shares was Star Combo Pharma in 2024 — This indicates how many shares 135.083 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Star Combo Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Star Combo Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Star Combo Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Star Combo Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Star Combo Pharma dividend history and estimates

In 2024, Star Combo Pharma paid a dividend amounting to 0 undefined. Dividend means that Star Combo Pharma distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Star Combo Pharma provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Star Combo Pharma’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Star Combo Pharma's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Star Combo Pharma Dividend History

DateStar Combo Pharma Dividend
20250 undefined
Star Combo Pharma does not pay out any dividends.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Star Combo Pharma.

Star Combo Pharma shareholders

%
Name
Stocks
Change
Date
36.27402 % Goldenstar Pharmaceutical Investment Ltd.49,000,000010/15/2024
28.25340 % Zhang (Jinxing)38,165,51006/30/2024
8.47552 % Zhang (Su)11,448,98006/30/2024
8.14315 % Lepu Medical (Europe) Cooperatief U.A.11,000,000010/15/2024
2.62149 % Certane Ct Pty. Ltd.3,541,178010/15/2024
2.54234 % DW & RL Pty. Ltd.3,434,269010/15/2024
1.66084 % Zuo (Liang)2,243,512010/15/2024
1.39174 % Shi (Jixiang)1,880,000150,00010/15/2024
0.88989 % Icomoon Pty. Ltd.1,202,09020,00010/15/2024
0.46120 % Eureka Technology Innovation & Investment Pty. Ltd.623,000010/15/2024
1
2

Star Combo Pharma Executives and Management Board

Mr. Jinxing Zhang

Star Combo Pharma Managing Director, Director (since 2016)
Compensation 198,198

Ms. Su Zhang

Star Combo Pharma Chief Executive Officer, Director
Compensation 193,833

Mr. Richard Allely

Star Combo Pharma Non-Executive Independent Chairman of the Board
Compensation 100,456

Dr. Ziye Sui

(43)
Star Combo Pharma Non-Executive Director
Compensation 19,800

Mr. James Ni

Star Combo Pharma Chief Financial Officer
Compensation 4,071
1
2

Star Combo Pharma Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Goldenmax Intl Technology A Stock
Goldenmax Intl Technology A
SupplierCustomer0,910,770,870,41
1

Most common questions regarding Star Combo Pharma

What is the P/E ratio of Star Combo Pharma 2025?

The Star Combo Pharma P/E ratio is 6.05.

What is the P/S ratio of Star Combo Pharma 2025?

The Star Combo Pharma P/S ratio is 1.12.

What is the Quality Investing of Star Combo Pharma?

The Quality Investing for Star Combo Pharma is 5/10.

What is the revenue of Star Combo Pharma 2025?

The Star Combo Pharma revenue is 28.24 M AUD.

How high is the profit of Star Combo Pharma 2025?

The Star Combo Pharma profit is 5.25 M AUD.

What is the business model of Star Combo Pharma

No history available for Star Combo Pharma.

What is the Star Combo Pharma dividend?

Star Combo Pharma pays a dividend of 0 AUD distributed over payouts per year.

How often does Star Combo Pharma pay dividends?

The dividend cannot currently be calculated for Star Combo Pharma or the company does not pay out a dividend.

What is the Star Combo Pharma ISIN?

The ISIN of Star Combo Pharma is AU0000004798.

What is the Star Combo Pharma ticker?

The ticker of Star Combo Pharma is S66.AX.

How much dividend does Star Combo Pharma pay?

Over the past 12 months, Star Combo Pharma paid a dividend of 0 AUD . This corresponds to a dividend yield of about 2.1 %. For the coming 12 months, Star Combo Pharma is expected to pay a dividend of 0 AUD.

What is the dividend yield of Star Combo Pharma?

The current dividend yield of Star Combo Pharma is 2.1 %.

When does Star Combo Pharma pay dividends?

Star Combo Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Star Combo Pharma?

Star Combo Pharma paid dividends every year for the past 1 years.

What is the dividend of Star Combo Pharma?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 2.1 %.

In which sector is Star Combo Pharma located?

Star Combo Pharma is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von Star Combo Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Star Combo Pharma from 10/31/2025 amounting to 0.005 AUD, you needed to have the stock in your portfolio before the ex-date on 10/14/2025.

When did Star Combo Pharma pay the last dividend?

The last dividend was paid out on 10/31/2025.

What was the dividend of Star Combo Pharma in the year 2024?

In the year 2024, Star Combo Pharma distributed 0 AUD as dividends.

In which currency does Star Combo Pharma pay out the dividend?

The dividends of Star Combo Pharma are distributed in AUD.

All fundamentals about Star Combo Pharma

Our stock analysis for Star Combo Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Star Combo Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.